Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (781 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone. GnRH is produced by neurons in the septum preoptic area of the hypothalamus and released into the pituitary portal blood, leading to stimulation of gonadotrophs in the anterior pituitary gland.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Gonadotropin Releasing Hormone; LHFSH Releasing Hormone; Releasing Hormone, LHFSH; LFRH; LH-Releasing Hormone; LH Releasing Hormone; LH-FSH Releasing Hormone; LH FSH Releasing Hormone.
Where it fits in the MeSH classification
- Broader topics
- Pituitary Hormone-Releasing Hormones; Oligopeptides
- Narrower topics
- Buserelin; Goserelin; Leuprolide; Nafarelin; Triptorelin Pamoate
- See also
- Receptors, LHRH; Kallmann Syndrome
Related concepts
- Luteinizing Hormone
- Follicle Stimulating Hormone
- Preoptic Area
- Hypothalamus
- Gonadotrophs
- Anterior Pituitary Gland
Research landscape
PubMed indexes 36,062 records tagged with the MeSH heading “Gonadotropin-Releasing Hormone” (counts retrieved 2026-10-31). 3,863 of them (10.7%) were published from 2020 onward, and the busiest period so far is through 1999 with 17,554 records.
Reviews account for 4,801 records (13.3%) and meta-analyses for 326. Randomized controlled trials number 2,303 (6.4%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 17,554 |
| 2000-2009 | 7,892 |
| 2010-2019 | 6,753 |
| 2020 onward | 3,863 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 4,801 | 13.3% |
| Meta-analyses | 326 | 0.9% |
| Randomized controlled trials | 2,303 | 6.4% |
Method: PubMed query "Gonadotropin-Releasing Hormone"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Identification of the FSH-RH as the other gonadotropin-releasing hormone | 2024 | Research article Design not recorded in structured metadata | 34 | cc by PMID 38937445 · DOI · PMC11211334 |
| Medical management of endometriosis | 2024 | Review article Design not recorded in structured metadata | 27 | cc by PMID 39159261 · DOI · PMC11356688 |
| SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability | 2023 | Research article Design not recorded in structured metadata | 22 | cc by PMID 38062045 · DOI · PMC10703890 |
| Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study | 2026 | Research article Design not recorded in structured metadata | 5 | cc by PMID 41538747 · DOI · PMC12904225 |
Identification of the FSH-RH as the other gonadotropin-releasing hormone [1]
Abstract reading summary — source excerpts
- Opening excerpt
- In vertebrates, folliculogenesis and ovulation are regulated by two distinct pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
- Closing excerpt
- Here, we propose the existence of the "dual GnRH model" in vertebrates that utilize both FSH-RH and LH-RH.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)
In vertebrates, folliculogenesis and ovulation are regulated by two distinct pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Currently, there is an intriguing consensus that a single hypothalamic neurohormone, gonadotropin-releasing hormone (GnRH), regulates the secretion of both FSH and LH, although the required timing and functions of FSH and LH are different. However, recent studies in many non-mammalian vertebrates indicated that GnRH is dispensable for FSH function. Here, by using medaka as a model teleost, we successfully identify cholecystokinin as the other gonadotropin regulator, FSH-releasing hormone (FSH-RH). Our histological and in vitro analyses demonstrate that hypothalamic cholecystokinin-expressing neurons directly affect FSH cells through the cholecystokinin receptor, Cck2rb, thereby increasing the expression and release of FSH. Remarkably, the knockout of this pathway minimizes FSH expression and results in a failure of folliculogenesis. Here, we propose the existence of the "dual GnRH model" in vertebrates that utilize both FSH-RH and LH-RH.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38937445 · DOI · PMC11211334
Medical management of endometriosis [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Purpose of reviewWhile laparoscopic surgery plays a key role in the management of endometriosis, symptoms commonly recur, and repeat surgery comes with increased risk.
- Closing excerpt
- The use of complementary and alternative medicines is also increasing in both volume and number of agents used.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (211 words)
Purpose of reviewWhile laparoscopic surgery plays a key role in the management of endometriosis, symptoms commonly recur, and repeat surgery comes with increased risk. Medical management, including hormonal and nonhormonal treatment, is vital in managing painful symptoms. This review summarizes recent evidence regarding various medical management options available to treat pelvic pain associated with endometriosis.Recent findingsEfficacy of dienogest vs. combined oral contraceptive on pain associated with endometriosis: randomized clinical trial.Once daily oral relugolix combination therapy vs. placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis.Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.SummaryAll symptomatic women with suspected endometriosis who are not desiring immediate fertility can be offered suppressive treatment to control symptoms and slow the progression of disease. First-line treatments include the combined oral contraceptive pill and progestogens. Second-line treatments include gonadotropin-releasing hormone agonists and antagonists but current guidelines recommend that these should be reserved for people whose symptoms fail to be controlled by first-line agents. The use of complementary and alternative medicines is also increasing in both volume and number of agents used.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39159261 · DOI · PMC11356688
SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Innervation of the hypothalamic median eminence by Gonadotropin-Releasing Hormone (GnRH) neurons is vital to ensure puberty onset and successful reproduction.
- Closing excerpt
- In all, our data reveal a role for Semaphorin-6A in regulating GnRH neuron patterning by tuning the median eminence vascular barrier and thereby controlling puberty onset.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (145 words)
Innervation of the hypothalamic median eminence by Gonadotropin-Releasing Hormone (GnRH) neurons is vital to ensure puberty onset and successful reproduction. However, the molecular and cellular mechanisms underlying median eminence development and pubertal timing are incompletely understood. Here we show that Semaphorin-6A is strongly expressed by median eminence-resident oligodendrocytes positioned adjacent to GnRH neuron projections and fenestrated capillaries, and that Semaphorin-6A is required for GnRH neuron innervation and puberty onset. In vitro and in vivo experiments reveal an unexpected function for Semaphorin-6A, via its receptor Plexin-A2, in the control of median eminence vascular permeability to maintain neuroendocrine homeostasis. To support the significance of these findings in humans, we identify patients with delayed puberty carrying a novel pathogenic variant of SEMA6A. In all, our data reveal a role for Semaphorin-6A in regulating GnRH neuron patterning by tuning the median eminence vascular barrier and thereby controlling puberty onset.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38062045 · DOI · PMC10703890
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study [4]
Abstract reading summary — source excerpts
- Opening excerpt
- PurposeTo evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor-positive early breast cancer (eBC).
- Closing excerpt
- ConclusionIn this cohort study analysis, extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (275 words)
PurposeTo evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor-positive early breast cancer (eBC).MethodsWe conducted a cohort study analysis on two prospectively collected data sets (the Young Women's Breast Cancer Study and IEO Breast Cancer Cohort). Eligible patients were diagnosed with eBC at age ≤40 years (between 2005 and 2016), had node-positive, hormone receptor-positive disease, and remained premenopausal after 5 years of adjuvant LHRHa with no evidence of recurrence. The primary end point was invasive breast cancer-free survival (IBCFS), calculated from the sixth year after the initiation of adjuvant endocrine therapy (ET; study baseline), and adjusted through the propensity score (PS) weighting analysis.ResultsA total of 501 patients were included in the analysis: 287 received eET for a median duration of 3.7 years (IQR, 2.3-5.0), including 48% tamoxifen monotherapy and 52% LHRHa plus tamoxifen or aromatase inhibitor. After a median follow-up of 7.3 years from the study baseline, the PS weighted IBCFS rates at 5 years were 85% in the eET group and 78% in the non-eET group (hazard ratio [HR], 0.63 [95% CI, 0.44 to 0.89]; P = .0135). The PS weighted distant recurrence-free survival rates at 5 years were 91% and 83% in the eET and non-eET group, respectively (cause-specific HR, 0.49 [95% CI, 0.31 to 0.79]). In both groups, bone fractures and major cardiovascular events were reported in 1% of patients.ConclusionIn this cohort study analysis, extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41538747 · DOI · PMC12904225
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Clinical Management of Congenital Hypogonadotropic Hypogonadism [5]
- Research article Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data [6]
- Research article Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium [7]
- Research article Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression [8]
- Research article The Gonadotropin-Releasing Hormone Pulse Generator [9]
- Research article KNDy Cells Revisited [10]
References
- Uehara SK, Nishiike Y, Maeda K, Karigo T, Kuraku S, Okubo K, et al.. Identification of the FSH-RH as the other gonadotropin-releasing hormone. . 2024. PMID 38937445 · DOI · PMC11211334
- Alonso A, Gunther K, Maheux-Lacroix S, Abbott J. Medical management of endometriosis. . 2024. PMID 39159261 · DOI · PMC11356688
- Lettieri A, Oleari R, van den Munkhof MH, van Battum EY, Verhagen MG, Tacconi C, et al.. SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability. . 2023. PMID 38062045 · DOI · PMC10703890
- Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, et al.. Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study. . 2026. PMID 41538747 · DOI · PMC12904225
- Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamäki J, et al.. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019. PMID 30698671 · DOI
- Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al.. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018. PMID 29718793 · DOI · PMC6804855
- Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, et al.. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm Res Paediatr. 2019. PMID 31319416 · DOI
- Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression. Mol Cell Endocrinol. 2018. PMID 29102564 · DOI · PMC5812824
- Herbison AE. The Gonadotropin-Releasing Hormone Pulse Generator. Endocrinology. 2018. PMID 30272161 · DOI
- Moore AM, Coolen LM, Porter DT, Goodman RL, Lehman MN. KNDy Cells Revisited. Endocrinology. 2018. PMID 30010844 · DOI · PMC6098225
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.